IMUX Immunic Inc. Forecast, Technical & Fundamental Analysis
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis... Show more
IMUX is expected to report earnings to rise 47.50% to -117 cents per share on November 05
Q3'26
Est.
$-1.18
Q2'26
Beat
by $0.43
Q1'26
Missed
by $1.00
Q4'25
Missed
by $0.53
Q3'25
Beat
by $0.02
The last earnings report on August 11 showed earnings per share of -80 cents, beating the estimate of -123 cents. With 83.65K shares outstanding, the current market capitalization sits at 226.23M.
A.I. Advisor
published General Information
General Information
a developer of pharmaceuticals and oral therapies for the treatment of chronic inflammatory and autoimmune diseases
A.I.dvisor indicates that over the last year, IMUX has been loosely correlated with IRD. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if IMUX jumps, then IRD could also see price increases.
Momentum Indicator for IMUX turns positive, indicating new upward trend
IMUX saw its Momentum Indicator move above the 0 level on August 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned positive. In of the 80 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for IMUX just turned positive on August 11, 2026. Looking at past instances where IMUX's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
IMUX moved above its 50-day moving average on August 11, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for IMUX crossed bullishly above the 50-day moving average on August 12, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IMUX advanced for three days, in of 262 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMUX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
IMUX broke above its upper Bollinger Band on August 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IMUX entered a downward trend on August 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.773) is normal, around the industry mean (20.281). P/E Ratio (0.000) is within average values for comparable stocks, (25.508). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.845). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.072).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IMUX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMUX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
